论文部分内容阅读
目的分析研究使用匹多莫德对小儿急性喘息性支气管炎治疗的效果及安全性,为临床治疗提供参考。方法 108例小儿急性喘息性支气管炎患儿,随机分为实验组和对照组,每组54例。对照组患者使用常规的控制喘憋和病原治疗,实验组患者在对照组治疗的基础上使用匹多莫德颗粒剂治疗,对比观察两组患者的治疗效果。结果治疗后,实验组患者总有效率96.30%优于对照组患者81.48%,差异有统计学意义(P<0.05)。实验组患者血清免疫球蛋白A(IgA)、免疫球蛋白G(Ig G)及免疫球蛋白M(Ig M)高于对照组患者,对比差异有统计学意义(P<0.05)。结论使用匹多莫德对小儿急性喘息性支气管炎患者的治疗效果较好,可以更好地改善患儿的免疫功能,值得应用。
Objective To analyze the effect and safety of pidotimod on children with acute asthmatic bronchitis and provide references for clinical treatment. Methods A total of 108 infants with acute asthmatic bronchitis were randomly divided into experimental group and control group, with 54 cases in each group. Patients in the control group were treated with conventional control of wheezing and pathogen treatment. Patients in the experimental group were treated with pidotimod on the basis of the control group, and the therapeutic effect was compared between the two groups. Results After treatment, the total effective rate of the experimental group was 96.30%, which was 81.48% of that of the control group, the difference was statistically significant (P <0.05). The serum IgA, Ig G and Ig M in the experimental group were significantly higher than those in the control group (P <0.05). Conclusion Pidotimod treatment of children with acute asthmatic bronchitis better treatment, can better improve the immune function in children, it is worth applying.